25. Lundberg E. Application of a versatile drift-compensating digital peak reader to the direct atomization of solids in graphite furnace atomic absorption spectroscopy. Appl Spectrosc 32,276-281 (1978 The absorption, distribution, and elimination pharmacokinetics of ABA and SA have recently been examined (2). Acetylsalicylic acid esterase (ASA esterase), a species of carboxylic ester hydrolase (EC 3.1.1) catalyzes hydrolysis of ASA to SA in blood, but methods for measuring ASA esterase (3-6) are poorly optimized. I have improved this assay by using a higher substrate concentration and adding Ca2 as an activator. As a result the ABA esterase activity measured in normal sera was 25-fold that earlier reported. I also carried out inhibition tests for comparison with similar published studies of other esterases in human serum.
,
Substrate.
Acetylsalicylic acid, 555 mmoIJL of ethanol (1 g of acetylsalicylic acid in 10 mL of ethanol). Sera. Samples from healthy subjects and patients were used either immediately after collection or after storing for various intervals to test the stability of the enzyme.
Hemolysates.
From five EDTA-stabilized blood samples, erythrocytes were washed three times with isotonic NaC1 (centrifugation: 650 x g, 5 mm), and hemolyzed at -18 #{176}C for 18-20 h.
Analytical
system. The determination of ABA esterase is based on measurement of SA formed in an incubation mixture of buffer, ASA, and sample. The protocol for this fixed-time incubation method is shown in Table 1 . Incubation was at 37 #{176}C for 30 mm, with a starting ASA concentration of 9.25 mmol/L. Corrections were made for nonen.zymatic hydrolysis of ABA during incubation and for the presence of pre-existing salicylate in the samples tested. 
Results
Choice of solvent for the substrate. Ethanol was chosen as the solution medium, because ABA is 60-fold more soluble in it than in aqueous solution and does not spontaneously Choice of buffer, pH, and temperature. Tris HC1 buffer was preferred because it has no effect on Ca2; a concentration of 300 mmoIJL was chosen to keep the pH constant at about 7.4
at 37 #{176}C after addition of the substrate and to allow a pH decrease of <0.10 on formation of salicylate and acetate. If the concentration of Tris HC1 buffer was increased to 500 mmol/L to minimize the change in pH, the reagent blank increased threefold.
ABA esterase has a pH maximum at 8.0 at 37 #{176}C ( 
Inhibitors.
I used various inhibitors of esterase, to compare the inhibition pattern with other known esterases.
Cholinesterase inhibitors such as neostigmine and echothiophate totally inhibited ASA esterase in serum at iO mol/L and 10-6 mol/L, respectively. LaC13 had only a mild depressive effect (10% at 5 mniol/L), whereas acetazolamide had no effect at 1 mmol/L. test (p >0.10) . Further ASA esterase activity was measured in hemolysates from five subjects. The mean value was 0.080 katimmol of hemoglobin (range 0.067-0.091 p.katlmmol Hb), corresponding to about 1.1 pkat per liter of hemolysate.
Precision.
The same sample assayed on 10 consecutive days gave a CV of 3.2% (.t = 4.01 ikat/L, SD = 0.13 4atJL).
Discussion
The limited aqueous solubility of ASA and the increasing reagent blank with higher concentrations of Tris HC1 buffer make it difficult to establish an optimal assay system for ABA esterase, but here these difficulties have been partly overcome. As high absorbances have been obtained for normal sera, the reaction interval can be changed from 30 to 10 mm, thus decreasing the percentage of the original ABA that is enzymatically and non-enzymatically hydrolyzed.
In earlier studies concerning ASA esterase determinations (3-5), the substrate concentration in the incubation In the present study I found the enzymatic hydrolysis of ABA at 37 #{176}C in serum from patients to be about 20% of the original substrate concentration of ASA per hour in the presence of CaC12, 170 mmolJL. It has previously been estimated to be 15-20% per hour at room temperature (2). This hydrolysis in plasma could be stopped by adding a cholinesterase inhibitor, as also reported by other investigators (2). But in whole blood only slight inhibition of ASA esterase activity was observed (2), probably ascribable to an esterase in erythrocytes that is resistant to the inhibitor. The nonenzymatic hydrolysis of ASA at 37 #{176}C in this study was about 10% per hour, but only 2.5% at room temperature (8) . But even in the frozen state ASA slowly hydrolyzes to SA because of an acid-base effect (2). Thus, reliable ASA and SA measurements can only be obtained if a cholinesterase inhibitor is present in the sample tubes and the sample is rapidly centrifuged and analyzed.
In several aspects the inhibition pattern for ASA esterase was similar to that reported for cholinesterase (EC 3.1.1.8) (8) , but differed from that observed for arylesterase (EC 3.1.1.2) (9). Both ASA esterase and cholinesterase are affected by cholinesterase inhibitors, unlike arylesterase. ABA esterase is inhibited only 10% at 5 mmol of LaC13 per liter, but arylesterase is totally inactivated at the same concentration (9) . ASA esterase and arylesterase also differ in regard to heat stability. Sixty percent of the activity of ASA esterase remained after 56 #{176}C for 30 mm in this study, but only 33% of arylesterase activity was left after 56 #{176}C for 5 mm (9).
There are few published methods for measuring ASA esterase in patients, although such determinations may be of clinical value because the biological half-life of SA is conditioned by the half-life of ASA, which in turn largely depends on the activity of ABA esterase (10). In cirrhotic patients the ASA esterase activity was more than halved (4). ASA esterase is present in gastric mucosa, but does not seem to be a significant factor per se in the etiology of chronic peptic ulcer (11); ASA esterase in the serum of such patients was not measured.
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